Luke Norton
@lukenortonsa.bsky.social
Associate Professor
@uthealthsa.bsky.social
Genetics, molecular biology and integrative physiology of metabolic diseases.
http://scholar.google.com/citations?user…
@uthealthsa.bsky.social
Genetics, molecular biology and integrative physiology of metabolic diseases.
http://scholar.google.com/citations?user…
Reposted by Luke Norton
We are thrilled to share our new preprint entitled “The origin and molecular evolution of the mammalian liver cell architecture” www.biorxiv.org/content/10.1...
October 15, 2025 at 12:51 PM
We are thrilled to share our new preprint entitled “The origin and molecular evolution of the mammalian liver cell architecture” www.biorxiv.org/content/10.1...
Pleased to share our recent article on the importance (or not!!) of lean mass preservation in patients with obesity participating in weight loss interventions. This was driven by Jeffery Bolte and Annie Smelter, two very talented students in the lab.
Worth a read for context on the "lean mass muscle loss" #obesity GLP-1 medicine debate. Keep an eye on muscle function and health, diet quality and resistance #exercise and not just the DXA scan www.sciencedirect.com/science/arti...
September 18, 2025 at 9:17 PM
Pleased to share our recent article on the importance (or not!!) of lean mass preservation in patients with obesity participating in weight loss interventions. This was driven by Jeffery Bolte and Annie Smelter, two very talented students in the lab.
Corrected for placebo, 14.4% of patients had a reduction in liver fibrosis with no worsening steatohepatitis 🤔.
The ESSENCE Trial Semaglutide 2.4mg qw in #MASH Fibrosis Stage 2 or 3. An improvement in liver histology at week 72 in the first 800 patients randomized, mean #weight loss 10.5% www.nejm.org/doi/full/10....
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | NEJM
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomize...
www.nejm.org
April 30, 2025 at 10:40 PM
Corrected for placebo, 14.4% of patients had a reduction in liver fibrosis with no worsening steatohepatitis 🤔.
Please check out our latest manuscript describing the spatial transcriptional function of TCF7L2. Blocking TCF7L2 activity disrupts important zonated pathways (i.e. bile, cholesterol and glutamine metabolism) and predisposes mice to diet induced hepatic fibrosis.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
The Spatial Transcriptional Activity of Hepatic TCF7L2 Regulates Zonated Metabolic Pathways that Contribute to Liver Fibrosis - Nature Communications
This study identifies transcription factor 7-like 2 (TCF7L2) as a key regulator of hepatic metabolic zonation, and demonstrates that disruption to the transcriptional activity of TCF7L2 exacerbates th...
www.nature.com
April 10, 2025 at 8:02 PM
Please check out our latest manuscript describing the spatial transcriptional function of TCF7L2. Blocking TCF7L2 activity disrupts important zonated pathways (i.e. bile, cholesterol and glutamine metabolism) and predisposes mice to diet induced hepatic fibrosis.
www.nature.com/articles/s41...
www.nature.com/articles/s41...